-
How BicD and MAP7 Activate Drosophila Kinesin-1
2026-09-10
The reference study shows that BicD and MAP7 activate homodimeric Drosophila kinesin-1 through distinct but complementary mechanisms. BicD relieves kinesin autoinhibition, whereas full-length MAP7 improves motor engagement with microtubules; together, they produce the strongest activation in the reconstituted system.
-
Potassium Channels and Renal Blood Flow in Sepsis
2026-09-10
This study shows that ATP-sensitive and calcium-activated potassium channels influence renal vascular responses during experimental sepsis in a context-dependent manner. Although channel blockers alone did not alter renal blood flow, glibenclamide or iberiotoxin intensified the fall in flow produced by norepinephrine or phenylephrine in septic rats, highlighting a potential risk of combining channel blockade with vasopressor therapy.
-
NHS-Biotin for Nanobody and Protein Assays
2026-09-09
NHS-Biotin combines efficient amine-reactive labeling with a short spacer that is useful for antibody detection, protein enrichment, and intracellular assay development. Paired with the peptidisc-assisted nanobody clustering strategy, it provides an orthogonal way to compare monomeric and multimeric binders without treating labeling chemistry as the assembly mechanism.
-
CSBTA Pharmacokinetics in MASH: Enzyme-Transporter Insights
2026-09-09
This 2025 study shows that MASH-like pathology can substantially alter the exposure, liver distribution, and hepatocyte accumulation of Corydalis saxicola Bunting total alkaloids and their major constituents. By combining UHPLC-MS/MS pharmacokinetics with transporter, microsomal metabolism, and expression analyses, it links disease-related pharmacokinetic variability to CYP450s, Oatp1b2, P-glycoprotein, and PXR-associated regulation.
-
BOP Reagent for Peptide and Prodrug Workflows
2026-09-08
BOP reagent enables controlled carboxyl group activation for amide bond formation, phenyl ester preparation, and blocked amino acid derivative workflows. This guide translates those bench advantages into a practical synthetic and assay-planning framework inspired by a carrier-free, ROS-responsive triterpene prodrug strategy for oral squamous cell carcinoma research.
-
Gut–Brain Cholinergic Signaling in Seizure Control
2026-09-08
Jia et al. identify a gut–vagus–brain cholinergic circuit through which Bacteroides fragilis suppresses seizures in mouse models and shows efficacy in a randomized trial involving pediatric refractory epilepsy. The study connects microbial ecology, colonic ChAT-positive cells, vagal transmission, and seizure control, providing a mechanistic framework for microbiota-targeted epilepsy research.
-
U0126-EtOH: MEK1/2 Inhibition for Pathway Studies
2026-09-07
U0126-EtOH enables controlled MEK1/2 inhibition across neuronal oxidative-stress, inflammation, and regenerative-patterning assays. This guide translates its noncompetitive mechanism into practical workflows, controls, spatially informed experiments, and troubleshooting strategies.
-
RIPA Lysis Buffer: Smarter Glioma Protein Workflows
2026-09-05
A translational strategy for connecting CSRP2–PRC1–PDGFRA biology with rigorous protein extraction, phospho-signaling analysis, immunoprecipitation, and orthogonal chromatin workflows in glioma research.
-
Neuromedin S (rat): GPCR Workflow Guide
2026-09-05
Neuromedin S (rat) (SKU B5466) provides a defined peptide agonist reagent for controlled neuromedin U receptor and GPCR/G protein signaling studies. It is intended for research workflows such as energy homeostasis regulation and stress response research, but not for diagnostic, therapeutic, or unsupported cross-species applications.
-
From DNA Delivery to Cuproptosis Insight
2026-09-04
A mechanistic and translational perspective on how Polyethylenimine Linear (PEI), MW 40,000 can support DNA-based validation of AC008406.3, cuproptosis, and docetaxel sensitivity in breast cancer research.
-
Protease Inhibitor Cocktail for DFCP1–ATGL Assays
2026-09-04
Protect DFCP1, ATGL, and associated lipid-droplet proteins from extraction-related degradation with a broad-spectrum, water-soluble inhibitor workflow. This guide shows how to use an EDTA-containing Protease Inhibitor Cocktail across Western blotting, Co-IP, tissue extraction, imaging support, and kinase-focused assays while managing metal-chelation constraints.
-
ATS-9R Enables Targeted Gene Delivery to Adipocytes
2026-09-03
The reference study introduced ATS-9R as a prohibitin-binding, non-viral carrier that selectively delivers nucleic acids to mature adipocytes. In obese mice, an ATS-9R/shFABP4 complex produced adipose-directed gene silencing, metabolic recovery, and more than 20% body-weight reduction, establishing a foundation for targeted gene delivery to white adipose tissue.
-
L-Threonine: A Strategic Variable in Metabolic Assays
2026-09-03
L-Threonine is more than an essential nutrient: it is a controllable experimental variable linking protein synthesis, central carbon metabolism, nutrient signaling, and assay interpretation. This article shows how translational researchers can pair defined L-Threonine workflows with sensitive alkaline phosphatase measurements while separating metabolic effects from direct enzyme inhibition.
-
DAPI Nuclear Stain Solution Protocol
2026-09-02
DAPI (4',6-Diamidino-2-Phenylindole) Nuclear Stain Solution provides a ready-to-use fluorescent DNA binding reagent for nuclear visualization, endpoint cell viability assessment, and selected apoptosis workflows. It is best suited to fixed or membrane-compromised samples analyzed by fluorescence microscopy or flow cytometry, not routine imaging of intact live cells.
-
Carvedilol Phosphate: Reading GPCR Bias in IRI
2026-09-02
Carvedilol Phosphate can serve as a mechanistic perturbation tool for separating adrenergic signaling from the hepatocyte–macrophage axis in ischemia–reperfusion research. This article connects its pharmacology and handling properties with the Arrb2–6-ketoLCA findings while defining what the evidence does—and does not—support.